BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31005212)

  • 1. Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival.
    Li C; Yan JL; Torheim T; McLean MA; Boonzaier NR; Zou J; Huang Y; Yuan J; van Dijken BRJ; Matys T; Markowetz F; Price SJ
    Radiother Oncol; 2019 May; 134():17-24. PubMed ID: 31005212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma.
    Kondo M; Uchiyama Y
    J Neuroradiol; 2018 Jul; 45(4):236-241. PubMed ID: 29274693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decoding the Interdependence of Multiparametric Magnetic Resonance Imaging to Reveal Patient Subgroups Correlated with Survivals.
    Li C; Wang S; Liu P; Torheim T; Boonzaier NR; van Dijken BR; Schönlieb CB; Markowetz F; Price SJ
    Neoplasia; 2019 May; 21(5):442-449. PubMed ID: 30943446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.
    Patel KS; Yao J; Raymond C; Yong W; Everson R; Liau LM; Nathanson D; Kornblum H; Wang C; Oughourlian T; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Sci Rep; 2020 Sep; 10(1):14819. PubMed ID: 32908231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.
    Yan JL; van der Hoorn A; Larkin TJ; Boonzaier NR; Matys T; Price SJ
    J Neurosurg; 2017 Jan; 126(1):234-241. PubMed ID: 27058207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging.
    Yamasaki F; Sugiyama K; Ohtaki M; Takeshima Y; Abe N; Akiyama Y; Takaba J; Amatya VJ; Saito T; Kajiwara Y; Hanaya R; Kurisu K
    Eur J Radiol; 2010 Mar; 73(3):532-7. PubMed ID: 19250783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
    Ellingson BM; Gerstner ER; Smits M; Huang RY; Colen R; Abrey LE; Aftab DT; Schwab GM; Hessel C; Harris RJ; Chakhoyan A; Gahrmann R; Pope WB; Leu K; Raymond C; Woodworth DC; de Groot J; Wen PY; Batchelor TT; van den Bent MJ; Cloughesy TF
    Clin Cancer Res; 2017 Oct; 23(19):5745-5756. PubMed ID: 28655794
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
    Ly KI; Vakulenko-Lagun B; Emblem KE; Ou Y; Da X; Betensky RA; Kalpathy-Cramer J; Duda DG; Jain RK; Chi AS; Plotkin SR; Batchelor TT; Sorensen G; Rosen BR; Gerstner ER
    Sci Rep; 2018 Nov; 8(1):17062. PubMed ID: 30459364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
    Chang W; Pope WB; Harris RJ; Hardy AJ; Leu K; Mody RR; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
    Tomography; 2015 Sep; 1(1):37-43. PubMed ID: 26740971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
    Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
    Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
    Rudra S; Hui C; Rao YJ; Samson P; Lin AJ; Chang X; Tsien C; Fergus S; Mullen D; Yang D; Thotala D; Hallahan D; Campian JL; Huang J
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):217-225. PubMed ID: 29502931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.